# A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

> **NCT06232707** · PHASE3 · WITHDRAWN · sponsor: **Celgene**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Alnuctamab
- **DRUG:** Pomalidomide
- **DRUG:** Daratumumab
- **DRUG:** Elotuzumab
- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT06232707
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-03
- **Primary completion:** 2025-11-16
- **Final completion:** 2030-09-21
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2024-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06232707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06232707, "A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06232707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*